Tenoretic 100

Slow Heart Rate, Atrial Fibrillation, Migraine + 14 more

Treatment

7 FDA approvals

20 Active Studies for Tenoretic 100

What is Tenoretic 100

Atenolol

The Generic name of this drug

Treatment Summary

Atenolol is a type of medication called a beta-blocker. It was developed in the 1980s and is used to treat various cardiovascular conditions. Research has shown that it may not be as effective as other medications in preventing cardiovascular disease and mortality in patients with high blood pressure. Atenolol may be more beneficial for some patients than others, depending on their age and other factors.

Tenormin

is the brand name

image of different drug pills on a surface

Tenoretic 100 Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Tenormin

Atenolol

1990

432

Approved as Treatment by the FDA

Atenolol, otherwise called Tenormin, is approved by the FDA for 7 uses like Hypertensive disease and Refractory Hypertension .

Hypertensive disease

Used to treat Refractory Hypertension in combination with Chlorthalidone

Refractory Hypertension

Used to treat Refractory Hypertension in combination with Chlorthalidone

Hypertensive disease

Helps manage High Blood Pressure (Hypertension)

Slow Heart Rate

Heart Attack

Hemodynamically Stable

Hypertension

Effectiveness

How Tenoretic 100 Affects Patients

Atenolol is a type of drug used to slow down the heart rate, reduce electrical conductivity, and lower the amount of work that the heart needs to do. This helps reduce the mismatch between oxygen supply and demand and can provide relief from angina pectoris symptoms. It also helps control arrhythmic conditions like atrial fibrillation. Atenolol also helps lower blood pressure, though not as much as other types of beta-blockers, and it does not act on the blood vessels directly. Common side effects of atenolol include fatigue, depression, and sleep disturbances. It can also cause

How Tenoretic 100 works in the body

Atenolol is a type of drug called a beta-blocker. It binds to beta receptors in the body, particularly those in the heart, and blocks them from responding to normal signals. By blocking these signals, atenolol helps reduce the heart rate and increase the strength of each beat. It also relaxes the smooth muscles of the bronchial tubes, which can help with breathing. Atenolol works by inhibiting certain proteins that control heart rate, contraction strength, and other important processes in the body.

When to interrupt dosage

The suggested amount of Tenoretic 100 is contingent upon the determined condition, such as Atrial Fibrillation, Migraine and Hypertensive disease. The dosage fluctuates as per the technique of administration (e.g. Tablet - Oral or Tablet) featured in the table below.

Condition

Dosage

Administration

Slow Heart Rate

, 50.0 mg, 100.0 mg, 25.0 mg, 50.0 mg/mg, 5.0 mg/mg, 2.5 mg/mg, 0.5 mg/mL

Tablet, Oral, Tablet - Oral, , Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Intravenous, Injection, solution, Injection, solution - Intravenous

Heart Attack

, 50.0 mg, 100.0 mg, 25.0 mg, 50.0 mg/mg, 5.0 mg/mg, 2.5 mg/mg, 0.5 mg/mL

Tablet, Oral, Tablet - Oral, , Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Intravenous, Injection, solution, Injection, solution - Intravenous

Chest Pain

, 50.0 mg, 100.0 mg, 25.0 mg, 50.0 mg/mg, 5.0 mg/mg, 2.5 mg/mg, 0.5 mg/mL

Tablet, Oral, Tablet - Oral, , Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Intravenous, Injection, solution, Injection, solution - Intravenous

Thyrotoxicosis

, 50.0 mg, 100.0 mg, 25.0 mg, 50.0 mg/mg, 5.0 mg/mg, 2.5 mg/mg, 0.5 mg/mL

Tablet, Oral, Tablet - Oral, , Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Intravenous, Injection, solution, Injection, solution - Intravenous

Hypertension

, 50.0 mg, 100.0 mg, 25.0 mg, 50.0 mg/mg, 5.0 mg/mg, 2.5 mg/mg, 0.5 mg/mL

Tablet, Oral, Tablet - Oral, , Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Intravenous, Injection, solution, Injection, solution - Intravenous

Atrial Fibrillation

, 50.0 mg, 100.0 mg, 25.0 mg, 50.0 mg/mg, 5.0 mg/mg, 2.5 mg/mg, 0.5 mg/mL

Tablet, Oral, Tablet - Oral, , Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Intravenous, Injection, solution, Injection, solution - Intravenous

Migraine

, 50.0 mg, 100.0 mg, 25.0 mg, 50.0 mg/mg, 5.0 mg/mg, 2.5 mg/mg, 0.5 mg/mL

Tablet, Oral, Tablet - Oral, , Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Intravenous, Injection, solution, Injection, solution - Intravenous

Secondary prevention Myocardial infarction

, 50.0 mg, 100.0 mg, 25.0 mg, 50.0 mg/mg, 5.0 mg/mg, 2.5 mg/mg, 0.5 mg/mL

Tablet, Oral, Tablet - Oral, , Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Intravenous, Injection, solution, Injection, solution - Intravenous

Migraine Disorders

, 50.0 mg, 100.0 mg, 25.0 mg, 50.0 mg/mg, 5.0 mg/mg, 2.5 mg/mg, 0.5 mg/mL

Tablet, Oral, Tablet - Oral, , Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Intravenous, Injection, solution, Injection, solution - Intravenous

Congestive Heart Failure

, 50.0 mg, 100.0 mg, 25.0 mg, 50.0 mg/mg, 5.0 mg/mg, 2.5 mg/mg, 0.5 mg/mL

Tablet, Oral, Tablet - Oral, , Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Intravenous, Injection, solution, Injection, solution - Intravenous

Syndrome

, 50.0 mg, 100.0 mg, 25.0 mg, 50.0 mg/mg, 5.0 mg/mg, 2.5 mg/mg, 0.5 mg/mL

Tablet, Oral, Tablet - Oral, , Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Intravenous, Injection, solution, Injection, solution - Intravenous

Coronary Artery Disease

, 50.0 mg, 100.0 mg, 25.0 mg, 50.0 mg/mg, 5.0 mg/mg, 2.5 mg/mg, 0.5 mg/mL

Tablet, Oral, Tablet - Oral, , Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Intravenous, Injection, solution, Injection, solution - Intravenous

Hypertensive disease

, 50.0 mg, 100.0 mg, 25.0 mg, 50.0 mg/mg, 5.0 mg/mg, 2.5 mg/mg, 0.5 mg/mL

Tablet, Oral, Tablet - Oral, , Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Intravenous, Injection, solution, Injection, solution - Intravenous

Hypertensive disease

, 50.0 mg, 100.0 mg, 25.0 mg, 50.0 mg/mg, 5.0 mg/mg, 2.5 mg/mg, 0.5 mg/mL

Tablet, Oral, Tablet - Oral, , Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Intravenous, Injection, solution, Injection, solution - Intravenous

Tachycardia, Ventricular

, 50.0 mg, 100.0 mg, 25.0 mg, 50.0 mg/mg, 5.0 mg/mg, 2.5 mg/mg, 0.5 mg/mL

Tablet, Oral, Tablet - Oral, , Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Intravenous, Injection, solution, Injection, solution - Intravenous

Hemodynamically Stable

, 50.0 mg, 100.0 mg, 25.0 mg, 50.0 mg/mg, 5.0 mg/mg, 2.5 mg/mg, 0.5 mg/mL

Tablet, Oral, Tablet - Oral, , Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Intravenous, Injection, solution, Injection, solution - Intravenous

Tachycardia, Ventricular

, 50.0 mg, 100.0 mg, 25.0 mg, 50.0 mg/mg, 5.0 mg/mg, 2.5 mg/mg, 0.5 mg/mL

Tablet, Oral, Tablet - Oral, , Buccal; Oral; Sublingual; Transmucosal, Tablet - Buccal; Oral; Sublingual; Transmucosal, Intravenous, Injection, solution, Injection, solution - Intravenous

Warnings

Tenoretic 100 has four contraindications and should not be employed with the conditions outlined in the table below.

Tenoretic 100 Contraindications

Condition

Risk Level

Notes

Heart Block

Do Not Combine

Shock, Cardiogenic

Do Not Combine

Sinus Bradycardia

Do Not Combine

Heart Failure

Do Not Combine

There are 20 known major drug interactions with Tenoretic 100.

Common Tenoretic 100 Drug Interactions

Drug Name

Risk Level

Description

4-Bromo-2,5-dimethoxyphenethylamine

Major

The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Atenolol.

4-Methoxyamphetamine

Major

The therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Atenolol.

Abediterol

Major

The therapeutic efficacy of Abediterol can be decreased when used in combination with Atenolol.

Adrafinil

Major

The therapeutic efficacy of Adrafinil can be decreased when used in combination with Atenolol.

Agrostis gigantea pollen

Major

The risk of a hypersensitivity reaction to Agrostis gigantea pollen is increased when it is combined with Atenolol.

Tenoretic 100 Toxicity & Overdose Risk

The toxic dose of atenolol in mice is 2g/kg when taken orally, 57mg/kg when taken intravenously, 134mg/kg when injected intramuscularly, and 400mg/kg when injected subcutaneously. In rats, the toxic dose is 2g/kg orally and 77mg/kg intravenously. The toxic dose in rabbits is 50mg/kg intravenously. Studies in rats and mice at doses of 300mg/kg per day, which is 150 times the maximum recommended human dose for 18-24 months, did not show any signs of carcinogenicity. However,

image of a doctor in a lab doing drug, clinical research

Tenoretic 100 Novel Uses: Which Conditions Have a Clinical Trial Featuring Tenoretic 100?

626 active clinical trials are currently being conducted to ascertain the potential of Tenoretic 100 in improving Atrial Fibrillation, Coronary Artery Atherosclerosis and Ventricular Tachycardia.

Condition

Clinical Trials

Trial Phases

Coronary Artery Disease

1 Actively Recruiting

Not Applicable

Atrial Fibrillation

103 Actively Recruiting

Not Applicable, Phase 4, Phase 1, Phase 3, Phase 2, Early Phase 1

Congestive Heart Failure

181 Actively Recruiting

Not Applicable, Phase 1, Early Phase 1, Phase 2, Phase 3, Phase 4

Thyrotoxicosis

0 Actively Recruiting

Migraine

52 Actively Recruiting

Phase 4, Phase 1, Not Applicable, Phase 3, Phase 2, Early Phase 1

Secondary prevention Myocardial infarction

0 Actively Recruiting

Heart Attack

25 Actively Recruiting

Not Applicable, Early Phase 1, Phase 4, Phase 2, Phase 3

Syndrome

3 Actively Recruiting

Phase 2, Phase 3, Phase 1

Migraine Disorders

1 Actively Recruiting

Phase 3

Tachycardia, Ventricular

0 Actively Recruiting

Hypertension

0 Actively Recruiting

Slow Heart Rate

2 Actively Recruiting

Not Applicable

Hemodynamically Stable

0 Actively Recruiting

Hypertensive disease

0 Actively Recruiting

Chest Pain

2 Actively Recruiting

Phase 2, Phase 3, Not Applicable

Tachycardia, Ventricular

0 Actively Recruiting

Hypertensive disease

41 Actively Recruiting

Not Applicable, Phase 3, Phase 1, Phase 2

Tenoretic 100 Reviews: What are patients saying about Tenoretic 100?

5

Patient Review

4/8/2012

Tenoretic 100 for High Blood Pressure

I found this medication effective at keeping my blood pressure low; however, it made me feel very sleepy and tired. I also had to urinate frequently.

4.7

Patient Review

6/9/2011

Tenoretic 100 for High Blood Pressure

Though it caused some pretty severe side effects like dry mouth and anxiety, this medication did lower my blood pressure from 150/100 to 130/90. It also helped remove the excess water weight I was carrying around in my face, legs, and ankles.

4.3

Patient Review

5/27/2009

Tenoretic 100 for High Blood Pressure

For two years, this was the only treatment that helped my high blood pressure. However, I developed diabetes and high uric acid levels, which may be due to the chlorthalidone.

4.3

Patient Review

2/13/2009

Tenoretic 100 for High Blood Pressure

This treatment effectively solved my high blood pressure problem, which was likely due to genetics.

4.3

Patient Review

1/30/2009

Tenoretic 100 for High Blood Pressure

I constantly felt disoriented, tired, and sick while taking this medication.

4

Patient Review

11/25/2013

Tenoretic 100 for High Blood Pressure

I still get dizzy sometimes when I stand up too quickly, but this treatment has otherwise been good.

3.7

Patient Review

7/2/2010

Tenoretic 100 for High Blood Pressure

Since using Tenoretic, I have had to urinate 60-80 times per day. This has also resulted in me chronic bed-wetting and needing 20-30 adult diapers each day.

3.7

Patient Review

8/31/2016

Tenoretic 100 for High Blood Pressure

I have experienced a number of adverse effects from this medication, including but not limited to rashes, itching, swelling, and vaginal bleeding. Additionally, it has made sitting and sleeping uncomfortable due to the pain it causes in my back. I would like to stop taking this medication as soon as possible.

3

Patient Review

2/24/2008

Tenoretic 100 for High Blood Pressure

2.3

Patient Review

1/18/2010

Tenoretic 100 for High Blood Pressure

I'm struggling with fatigue still, but this treatment has been good so far.

2.3

Patient Review

4/8/2010

Tenoretic 100 for High Blood Pressure

I've found it difficult to maintain a consistent blood pressure while taking this medication. My readings have varied widely, from 189/84 to 130/60.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about tenoretic 100

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the generic name for tenoretic?

"Atenolol and chlorthalidone are available as 50mg/25mg+ and 100mg/25mg tablets. Both tablet formulations are scored."

Answered by AI

Is tenoretic the same as atenolol?

"This slows down the heart rate and decreases the force of heart muscle contraction. Chlorthalidone is a thiazide "water pill" (diuretic) that helps prevent your body from absorbing too much salt and keeps your potassium levels from getting too low.

Tenoretic is a combination of Atenolol, a selective beta blocker, and Chlorthalidone, a thiazide diuretic. Atenolol works by blocking certain natural compounds that may bind to receptors on the heart, which slows down the heart rate and decreases the force of heart muscle contraction. Chlorthalidone helps prevent your body from absorbing too much salt and keeps your potassium levels from getting too low."

Answered by AI

What drug class is tenoretic?

"Tenoretic is a prescription medicine used to treat the symptoms of High blood pressure (Hypertension). Tenoretic may be used alone or with other medications. Tenoretic is a combination of two drugs, a thiazide diuretic (water pill) and a beta-blocker. Beta-blockers work by slowing down the heart and reducing the amount of blood it pumps out. Thiazide diuretics help reduce the amount of water in the body by increasing the amount of urine produced."

Answered by AI

What is tenoretic used for?

"Atenolol is a beta-blocker that works by relaxing blood vessels and reducing heart rate. Chlorthalidone is a "water pill" (diuretic) that causes you to make more urine, which helps your body get rid of extra salt and water.

This medication is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This product contains 2 medications: atenolol and chlorthalidone. Atenolol is a beta-blocker that works by relaxing blood vessels and reducing heart rate. Chlorthalidone is a "water pill" (diuretic) that causes you to make more urine, which helps your body get rid of extra salt and water."

Answered by AI

Clinical Trials for Tenoretic 100

Image of Allegheny General Hospital in Pittsburgh, United States.

Bachmann's Bundle vs Right Atrial Appendage Pacing for Atrial Fibrillation

18+
All Sexes
Pittsburgh, PA

Participants will be randomly assigned to one of two clinical treatment Arms, both of which are standard care procedures performed in the right atrium (RA): Arm A: Pacing from the Bachmann's Bundle (BB) in the right atrium (upper right chamber of the heart) Arm B: Pacing from the right atrial appendage (RAA - a sac attached to the right atrium) Neither of these treatments are experimental; both are routinely performed by Electrophysiologists in the clinical setting. The purpose of this study is to compare side by side these two treatments and evaluate if one is better than the other. After the procedure, participants will be followed for one year. Medical record data will be collected, and a blood sample will be collected upon enrollment and at one year after implantation. Research-related surveys will be completed at the standard-care 3-, 6-, and 12-month visits.

Recruiting
Has No Placebo

Allegheny General Hospital

Joshua Silverstein, MD

Medtronic

Image of Cedars-Sinai Medical Center in Los Angeles, United States.

Barber and Pharmacist Coordination for High Blood Pressure

35 - 79
Male
Los Angeles, CA

The original, "Cut Your Pressure Too: The LA Barbershop Blood Pressure Study (LABBPS)" (NCT02321618) was a highly successful cluster-randomized trial of a community centered blood pressure (BP) reduction program focused on Non-Hispanic (NH) black men who experience the highest rates of hypertension (HTN) and its complications. Patrons of 52 barbershops in Los Angeles County were randomly assigned to either an intervention arm in which barbers encouraged meetings with trained clinical pharmacists who provided HTN treatment in the barbershops or a control arm in which barbers provided educational pamphlets on HTN and encouraged physician appointments. After 6 months, the intervention group had a statistically significant reduction in systolic BP (SBP) of 21.6 mmHg compared to the control group. Results were durable at 1 year. Thereafter, a pilot study (NCT03726710) aimed at improving the efficiency of the barbershop model of HTN care by substituting in-person visits with video visits once BP was at goal was undertaken in 10 hypertensive barbershop patrons. The intervention effect was unchanged. The current study represents Aim 3 of an NIH funded renewal application entitled, "Barber and Pharmacist Coordination to Improve Blood Pressure Management in Black Men." It will build upon the foundational work of the original study and telemedicine pilot by evaluating the efficacy of a fully remote hypertension management program.

Waitlist Available
Has No Placebo

Cedars-Sinai Medical Center

Christine Albert, MD, MPH

Image of Foothills Medical Center in Calgary, Canada.

Spinal Cord Stimulation for High Blood Pressure

18+
All Sexes
Calgary, Canada

High blood pressure, also called hypertension, raises the risk of heart disease, stroke, and kidney disease. Medications work well for many people, but some people still have blood pressure that stays too high, or they have side effects from their medications. Researchers are looking for treatments that do not involve taking more medication. Nerves help control blood pressure by changing how blood vessels tighten and how hard the heart pumps. Because of this, treatments that act on nerves may be able to lower blood pressure. Spinal cord stimulation is a treatment already used to manage long-term pain. It uses a small device, placed under the skin during a standard operation, that sends mild electrical signals to the spine. Laboratory studies suggest that stimulating the lower part of the mid-back may also lower blood pressure, but this has not been carefully studied in people who already use these devices. This study will look at whether changing the settings on a spinal cord stimulator affects blood pressure. About 11 adults who have high blood pressure and who already have a spinal cord stimulator for long-term pain. No new device will be placed, and no surgery or other invasive procedure will be done for this study. Participants attend a series of study visits. At each visit, trained staff record blood pressure and heart rate while the stimulator is turned on, turned off, and set to other settings that the person's care team has approved and that the person finds comfortable. There are rest breaks between each setting. Over successive visits, the study team works to identify the settings that best lower blood pressure. Participants can stop at any time, and their usual settings are restored at the end of each visit. The study will also look at whether this kind of testing is practical and comfortable for participants. The results will help researchers decide whether larger studies of spinal cord stimulation for blood pressure control are worth doing.

Waitlist Available
Has No Placebo

Foothills Medical Center

Aaron Phillips, PhD

Have you considered Tenoretic 100 clinical trials?

We made a collection of clinical trials featuring Tenoretic 100, we think they might fit your search criteria.
Go to Trials
Image of University of Colorado, Anshcutz Medical Campus in Aurora, United States.

Intravenous Acetate for Alcohol Withdrawal Syndrome

18+
All Sexes
Aurora, CO

Alcohol withdrawal syndrome is a highly morbid condition affecting a substantial percentage of patients hospitalized who have alcohol use disorders, estimated at 5-6% of all hospitalized patients. Standard treatment paradigms for alcohol withdrawal syndrome have common and serious side effects, and do not fully address this condition's underlying pathophysiology. This study will examine the feasibility and safety of administering intravenous acetate, an alcohol metabolite and alternative brain fuel, as an adjunctive treatment for alcohol withdrawal in hospitalized patients that will to set the stage for future investigations of its efficacy as an adjunctive treatment in the hospital setting.

Phase 1 & 2
Waitlist Available

University of Colorado, Anshcutz Medical Campus

Ellen Burnham, MD

Have you considered Tenoretic 100 clinical trials?

We made a collection of clinical trials featuring Tenoretic 100, we think they might fit your search criteria.
Go to Trials
Image of University of Colorado Anschutz in Denver, United States.

HEROIC Program for Heart Failure

18+
All Sexes
Denver, CO

This study will test the mechanisms of a multi-component, nurse-led, primary palliative care intervention, HEart failure Resilience Intervention for Caregivers (HEROIC) to improve caregiver mental well-being, patient health-related quality of life and unplanned acute care in the setting of advanced heart failure. The investigators will conduct a multi-site, randomized controlled trial to test proposed mechanisms of action in a large sample (N=500) of persons with heart failure and the caregivers. The investigators will also examine variation in response to HEROIC components by heart failure subgroup (ventricular assist device, heart transplant or medically managed heart failure).

Phase 2
Waitlist Available

University of Colorado Anschutz (+1 Sites)

Martha Abshire Saylor, PhD, RN

Image of Norton Heart & Vascular Institute - Advanced Heart Failure & Recovery Program in Louisville, United States.

Values-Based Communication for Heart Failure

18 - 105
All Sexes
Louisville, KY

Living with heart failure for adults over age 50 is hard. Older adults have to take many medicines to address heart failure and other health problems. That group of individuals must decide which medications to take and which devices to use to support heart health. Doctors, nurses, and social workers help patients understand these options but do not always know what is most important to them. Talking with patients about what the patients are hoping for, what the patients are worried about, and how much the patients understand about the illness is called a serious illness conversation, and it is hard to do. Doctors, nurses, and social workers are very busy and worry about upsetting patients by bringing up hard topics. The Serious Illness Care Program helps doctors, nurses, and social workers have these conversations by giving the staff a script to follow on what to say. The program also includes ways to make sure staff remember to have the conversation, a brief training, and how to document what is said during the conversation. But, nobody has studied the Serious Illness Care Program in a heart failure clinic, so it has not been customized to meet the needs of heart failure teams or older adults with heart failure. Many programs that are supposed to help patients fail in the real world. One reason is that patients do not include the needs of those who will receive and deliver it. Before this project, the team interviewed heart failure doctors, nurses, social workers, and other staff at a heart failure clinic. As well as interviewing older adults and care partners. The team asked staff how the Serious Illness Care Program can be changed to fit the needs and work in the clinic. The program includes a conversation guide that helps the team know what to say, so the study team asked patients and care partners what the thoughts on the language used and the topics covered. Then, the team practiced putting the program in place at the clinic and trained clinicians on using the Serious Illness Care Program with older adults and family members. Now the team wants to see if the heart failure team likes it and if it is doable. The team will also ask patients and care partners about the conversation and about feelings of anxiety before, during, and after the conversation. Lastly, the team will ask the individuals before and after the conversation about patients' knowledge of heart failure and how prepared the care partner feels to care for the individual. The team also want to explore how the program helps clinicians understand patients' symptoms, quality of life, and illness knowledge. Ultimately, this project establishes a structured framework to facilitate goals-of-care discussions between heart failure teams, patients, and families. These conversations empower patients to make immediate and future medical decisions aligned with personal values and lifestyle preferences. This values-based decision-making process optimizes care delivery and supports patients in achieving optimal health outcomes.

Waitlist Available
Has No Placebo

Norton Heart & Vascular Institute - Advanced Heart Failure & Recovery Program

Image of Science and Engineering Innovation and Research Building (SEIR), University of Texas at Arlington in Arlington, United States.

Alcohol Abstinence for High Blood Pressure

26 - 49
All Sexes
Arlington, TX

The purpose of this study is to learn whether avoiding alcohol can improve heart and blood vessel health in adults who regularly drink alcohol and have high blood pressure. High blood pressure is a major risk factor for cardiovascular disease (CVD), including heart attack and stroke. In this randomized, controlled trial, men and women aged 26 to 49 years who regularly consume alcohol and have high blood pressure will be assigned by chance to either stop drinking alcohol or continue their usual drinking habits for 8 weeks. Researchers will compare changes in blood pressure and other cardiovascular disease risk factors between the two groups. The information gained from this study may help researchers and health care providers better understand the effects of alcohol consumption on cardiovascular health and whether alcohol abstinence can reduce heart disease risk, especially in adults with high blood pressure.

Recruiting
Has No Placebo

Science and Engineering Innovation and Research Building (SEIR), University of Texas at Arlington

Have you considered Tenoretic 100 clinical trials?

We made a collection of clinical trials featuring Tenoretic 100, we think they might fit your search criteria.
Go to Trials